Risk factor
Very poor trading liquidity
Profitability factor
Favourable analyst view
About
Lumibird SA specializes in the development, manufacturing, and commercialization of laser devices. Headquartered in Lannion, Bretagne, the company employs 541 dedicated full-time staff. Its extensive product offering includes various laser types such as compact pulsed and double-pulse Nd lasers, customizable laser systems, flash-lamp pumped lasers, diode-pumped solid-state lasers, semiconductor laser modules, and powerful intense pulsed light instruments. Lumibird provides its advanced laser solutions to a broad spectrum of clients, spanning industrial, scientific, and medical sectors. The firm operates globally through key subsidiaries, including Quantel Medical, which focuses on diagnostic ocular ultrasound systems and surgical lasers; Quantel USA, renowned for designing and producing fiber, glass, and tunable laser systems; and Quantel Derma AT, which concentrates on laser technology for dermatological and aesthetic applications.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, overpriced on
Target Price
The average target price of LBIRD.PA is 32.2 and suggests 39.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to